3 active not recruiting, 2 completed, 2 unknown, 1 not yet recruiting. 2 Not applicable, 2 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Unknown 2 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 2 | 2 | Active not recruiting 2 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Resectable Soft Tissue Sarcoma: new trials by email Literature Review of Resectable Soft Tissue Sarcoma trials Research Report on Resectable Soft Tissue Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall Biospecimen Collection, Computed Tomography, Doxorubicin - Resectable Liposarcoma, Resectable Soft Tissue Sarcoma | Phase 3 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 228 | 2026-12-01 | 2026-09-16 |
| Multiparametric Quantitative MRI and Response to Neoadjuvant Radiotherapy for Soft-tissue Sarcoma Neoadjuvant RT, Pre-radiotherapy mpMRI, Post-radiotherapy mpMRI - Soft Tissue Sarcoma, Adult Soft Tissue Sarcoma | Not applicable | Unknown | Centre Leon Berard | 25 | 2023-04-21 | 2023-10-30 |
| An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas Fluorodopa F 18, Magnetic Resonance Imaging, Positron Emission Tomography - Recurrent Soft Tissue Sarcoma, Resectable Soft Tissue Sarcoma | Completed | Mayo Clinic | 9 | 2022-11-10 | 2025-07-10 | |
| Adjuvant Versus Neo-adjuvant Radiotherapy in Patients With Resectable Soft Tissue Sarcoma in Extremities : Wound Complications surgical resection with safety margin - Resectable Soft Tissue Sarcoma, Extremities | Not applicable | Unknown | Ain Shams University | 20 | 2021-09-01 | 2023-05-17 |
| Radiation Therapy Before Surgery for Localized, Resectable Soft Tissue Sarcoma of the Extremity and Superficial Trunk Hypofractionated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration - Resectable Soft Tissue Sarcoma, Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Phase 2 | Active not recruiting | Mayo Clinic | 120 | 2020-11-30 | 2026-02-04 |
| Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma Definitive Surgical Resection, Nanoplexed Poly I:C BO-112, Nivolumab - Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 14 | 2020-10-14 | 2026-03-10 |
| Shorter Course, Hypofractionated Pre-Surgery Radiation Therapy in Treating Patients With Localized, Resectable Soft Tissue Sarcoma of the Extremity of Superficial Trunk Hypofractionated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration - Resectable Soft Tissue Sarcoma, Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 122 | 2018-12-17 | 2026-09-14 |
| Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma Navtemadlin, Radiation Therapy, Surgical Procedure - Resectable Soft Tissue Sarcoma, Soft Tissue Sarcoma | Phase 1 | Completed | National Cancer Institute (NCI) | 39 | 2018-06-20 | 2025-09-23 |
Sarcoma (4) · Dermatofibrosarcoma (1) · Histiocytoma, Malignant Fibrous (1) · Leiomyosarcoma (1) · Neoplasms (1) · Neurofibrosarcoma (1) · Pathologic Complete Response (1) · Sarcoma, Synovial (1)
Neoplasms by Histologic Type (4) · Neoplasms, Connective and Soft Tissue (4) · Neoplasms (3) · Disease Attributes (1) · Disease Progression (1) · Fibrosarcoma (1) · Histiocytoma (1) · Neoplasms, Connective Tissue (1) · Neoplasms, Fibrous Tissue (1) · Neoplasms, Muscle Tissue (1) · Neoplasms, Nerve Tissue (1) · Nerve Sheath Neoplasms (1) · Nervous System Diseases (1) · Nervous System Neoplasms (1) · Neurofibroma (1)
Radiation (4) · Radiotherapy (3) · Surgical Procedures, Operative (3) · Magnetic Resonance Spectroscopy (2) · Radiation Dose Hypofractionation (2) · 2-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid (1) · BO-112 (1) · Doxorubicin (1) · Ifosfamide (1) · Nivolumab (1) · Radiotherapy, Intensity-Modulated (1) · Specimen Handling (1) · Transurethral Resection of Bladder (1) · fluorodopa F 18 (1) · navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid (1)
Mayo Clinic (2) · Ain Shams University (1) · Centre Leon Berard (1) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Ohio State University Comprehensive Cancer Center (1)
United States (6) · Egypt (1) · France (1)
Beverly A Guadagnolo (1) · David A Liebner (1) · Deanna Hasenauer, Ph.D. (1) · Meng X Welliver (1) · Safia K. Ahmed, M.D. (1) · Vishruth Reddy, MD, PhD (1)
PMID 32767659, PMID 32827353, PMID 36343656, PMID 39192597, PMID 40389098
K08CA245181 (1), U10CA180868 (1)